Clinical Decision Support Algorithm to Predict Diabetic Retinopathy


Diabetic retinopathy (DR), a complication of diabetes, is a leading cause of blindness among working-aged adults globally. In its early stages, DR is symptomless, and can only be detected by an annual eye exam. Once the disease has progressed to the point where vision loss has occurred, the damage is irreversible. Consequently, early detection is quintessential in treating DR. Two barriers to early detection are poor patient compliance with the annual exam and lack of access to specialists in rural areas. This research is focused on developing and validating new, cost-effective predictive technologies that can improve early screening of DR. Our overall objective is to develop and implement an entire suite of tools to detect diabetes complications in order to augment care for underserved rural populations in the US and internationally.

Full Title of Study: “Validating a Clinical Decision Support Algorithm Developed With Demographic, Co-morbidity, and Lab Data to Diagnose, Stage, Prevent, and Monitor a Patient’s Diabetic Retinopathy”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: August 2022


  • Other: risk factors for diabetic retinopathy
    • Demographic variables: gender, race, marital status, urban rural status. Co-morbidity variable: neuropathy, nephropathy, peripheral circulatory, ketoacidosis, hyperosmolarity Lab tests variables: alanine aminotransferase (ALT), albumin serum, anion gap, aspartate aminotransferase, blood urea nitrogen, calcium serum, chloride serum, creatinine serum, glucose serum plasma, hematocrit, hemoglobin, mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MPV), potassium serum, protein total serum, red blood cell (RBC) count, sodium serum, white blood cell (WBC) count

Clinical Trial Outcome Measures

Primary Measures

  • Diabetic retinopathy indicator (yes/no)
    • Time Frame: March, 2019
    • Diabetic patients with 362.0x ICD-9 codes are classified as DR patient

Participating in This Clinical Trial

Inclusion Criteria

For diabetic patients with DR:

  • With 250.xx diabetes and 362.0x DR ICD-9 codes – All variables are complete within the observation window For diabetic patients without DR: – With 250.xx diabetes ICD-9 codes – Without 362.0x DR ICD-9 codes – All variables are complete within the observation window

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Oklahoma State University Center for Health Sciences
  • Collaborator
    • Oklahoma State University
  • Provider of Information About this Clinical Study
    • Principal Investigator: William Paiva, Executive Director – Oklahoma State University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.